- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion in Ireland
Total 10 results
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
BayerCompletedSolid Tumors Harboring NTRK FusionUnited States, Belgium, Italy, Germany, Australia, Spain, Singapore, Denmark, France, Ireland
-
BayerActive, not recruitingSolid Tumors Harboring NTRK FusionUnited States, China, Poland, Australia, Germany, Japan, Canada, Italy, Czechia, Spain, Turkey, United Kingdom, Sweden, Netherlands, France, Switzerland, Korea, Republic of, Denmark, Ireland, Israel, Ukraine
-
PfizerTerminatedLocally Advanced or Metastatic Solid Tumors | Genes, BRCA 1United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
TYK Medicines, IncRecruitingMetastatic Solid Tumor | Locally Advanced Solid TumorUnited States
-
BayerActive, not recruitingSolid Tumors Harboring NTRK FusionUnited States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
-
Aadi Bioscience, Inc.Active, not recruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmUnited States, Korea, Republic of, Puerto Rico
-
Deciphera Pharmaceuticals LLCCompletedLocally Advanced or Metastatic Solid TumorUnited States
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India